Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Gilead's Sofosbuvir for Hepatitis C Meets Primary Endpoint in Fourth Pivotal Phase 3 Study

Initial Regulatory Filings Planned for Q2 2013. Gilead Sciences (Nasdaq:GILD) today announced topline results from the Phase 3 FUSION study evaluating 12- and 16-week courses of therapy with the once-daily nucleotide sofosbuvir plus ribavirin (RBV) in treatment-experienced patients with genotype 2 or 3 chronic hepatitis C virus (HCV) infection who failed prior treatment.

Published
19 February 2013
From
Gilead press release
Triple trouble: infection with hepatitis B increases risk of death for people with HIV and hepatitis C co-infection

Infection with hepatitis B virus (HBV) is associated with a poorer prognosis for people living with HIV who are co-infected with hepatitis C virus (HCV), Spanish investigators

Published
19 February 2013
By
Michael Carter
Combining tenofovir with FTC or 3TC boosts chances of HBV suppression for people co-infected with HIV

A study involving people co-infected with HIV and hepatitis B virus (HBV) shows that antiretroviral therapy that combines tenofovir with FTC or 3TC has the best chance

Published
19 February 2013
By
Michael Carter
A 'Killer' of a Reason to Treat Hepatitis C: Video

Dr. David Johnson, Professor of Medicine and Chief of Gastroenterology at Eastern Virginia Medical School in Norfolk, Virginia, discusses the treatment of hepatitis C in patients with cirrhosis.

Published
18 February 2013
From
Medscape (requires registration)
Victrelis (boceprevir) label updates

On February 13, 2013, FDA approved changes to the Victrelis (boceprevir) label to expand the indication to include the treatment of prior null responders.

Published
18 February 2013
From
FDA
Drug interaction warning for hepatitis C: serious side effects when using telaprevir and bosentan

A medical team in Paris, France, has reported an unexpected and disturbing drug interaction between a drug used to treat pulmonary arterial hypertension—bosentan (Tracleer)—and the HCV drug telaprevir. The interaction led to serious side effects.

Published
15 February 2013
From
CATIE
Have a heart, save my liver!

Today, on the occasion of Valentine’s Day, Médecins du Monde and Treatment Action Group (TAG) launch an action urging pharmaceutical giants Merck and Roche to drop their exorbitant prices for pegylated interferon, an effective hepatitis C (HCV) treatment.

Published
14 February 2013
From
HepCoalition.org
Study: One-third of hepatitis B and C cases in Pakistan are preventable

Approximately one-third of all hepatitis B and C cases in Pakistan could be prevented by interventions directed towards a few modifiable risk factors, according to a recent study.

Published
14 February 2013
From
Vaccine News Daily (blog)
More evidence of sexual transmission of hepatitis C among HIV-positive gay men in the US

Investigators in the US have found a high incidence of hepatitis C virus (HCV) infection among HIV-positive gay men. Annual incidence was 1.6% – the highest ever

Published
14 February 2013
By
Michael Carter
HCV polymerase inhibitor mericitabine boosts interferon/ribavirin cure rate

A 24-week response-guided triple regimen consisting of Roche's NS5B polymerase inhibitor mericitabine plus pegylated interferon and ribavirin produced a greater likelihood of sustained viral suppression than a 48-week course of pegylated interferon/ribavirin alone, according to a report in the January 28, 2013, online advance edition of Hepatology.

Published
13 February 2013
From
HIVandHepatitis.com

Filter by country